Enteris BioPharma leverages its Peptelligence® platform to build long-term relationships with companies that recognize the business value and patient advantages of developing orally delivered peptide and small molecule therapeutics.
Peptides and small molecules with poor oral absorption are typically delivered by injection, which can mean poor patient compliance and limited market opportunities for drugmakers. Working with pharmaceutical partners, we understand the nuances of drug development and we help remove obstacles by creating proprietary, patent-protected oral formulations that can have game-changing benefits over the original compound, be it making a new molecular entity that has yet to enter clinical trials more attractive to patients or breathing life back into a successful, but aging compound that’s approaching the end of its product life cycle.
Interested in hearing more about the role Peptelligence® can play in new drug development and life cycle management? Contact us today to learn how you can partner with Enteris BioPharma.
CONTACT US
